Polymorphic hydroxylation of perhexiline in vitro

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 635-638

  Sorensen L B ^a   Sorensen R N ^a   Miners, J O ^a   Somogyi, A A ^b   Grgurinovich, N ^a   Birkett, D J ^a,c  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

CYPD2D6; Cytochrome P450; In vitro; In vivo extrapolation; Metabolism; Perhexiline; Polymorphism

Indexed keywords

COUMARIN; CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; GESTODENE; MEPHENYTOIN; PERHEXILINE; QUINIDINE; SULFAPHENAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; ENZYME KINETICS; ENZYME POLYMORPHISM; ENZYME SPECIFICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; GENOTYPE; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; PERHEXILINE; POLYMORPHISM, GENETIC; QUINIDINE;

EID: 0038804137     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01805.x     Document Type: Article

References (21)

1. Beaugrand M, Poupon R, Levy VG, Callard P, Lageron A, Lecomte D et al. Hepatic lesions due to perhexiline maleate. Gastroenterol Clin Biol 1978; 2: 579-588.
2. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979; 76: 170-177.
3. Forbes GB, Rake MO, Taylor DJ. Liver damage due to perhexiline maleate. J Clin Pathol 1979; 32: 1282-1285.
4. Hay DR, Gwynne JF. Cirrhosis of the liver following therapy with perhexilme maleate. NZ Med J 1983; 96: 202-204.
5. Paliard P, Vitrey D, Fournier G, Belhadjali J, Patricot L, Berger F. Perhexiline maleate-induced hepatitis. Digestion 1978; 17: 419-427.
6. Lhermitte F, Fardeau M, Chedru F, Mallecourt J. Polyneuropathy after perhexiline maleate therapy. BMJ 1976; 1: 1256.
7. Singlas E, Goujet MA, Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 1978; 14: 195-201.
8. Jallon P, Loiseau P, Orgogozo JM, Singlas E. Polyneuropathy with normal metabolism of perhexiline maleate. Ann Neurol 1978; 4: 385-386.
9. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. BMJ 1982; 284: 295-299.
10. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. Am Heart J 1983; 105: 159-161.
11. Wright GJ, Leeson GA, Zeiger AV, Lang JF. Proceedings: The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 1973; 49 (Suppl 3): 8-15.
12. Button IK, Davies HR, Zeitz CJ, Wuttke RD, Horowitz JD. Adverse reactions to perhexiline during short and long-term therapy. Aust NZ J Med 1993; 23: 599.
13. Horowitz JD, Morris PM, Drummer OH, Goble AJ, Louis WJ. High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci 1981; 70: 320-322.
14. Amoah AG, Gould BJ, Parke DV. Single-dose pharmacokinetics of perhexiline administered orally to humans. J Chromatogr A 1984; 305: 401-409.
15. Cooper RG, Evans DA, Price AH. Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 1987; 32: 569-576.
16. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25: 1057-1064.
17. Cooper RG, Evans DA, Whibley EJ. Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 1984; 21: 27-33.
18. Robson RA, Matthews AP, Miners JO et al. Characterisation of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol 1987; 24: 293-300.
19. Holford NHG. MKMODEL: a modelling tool for microcomputers. Pharmacokinetic evaluation and comparison with standard computer programs. Clin Exp Pharmacol Physiol 1985; 9: 95.
20. Sallustio BC, Westley IC, Morris RG. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady state dose. Br J Clin Pharmacol 2002; 54: 107-114.
21. Hussein R, Charles BG, Morris RG, Rasiah RL. Population pharmacokinetics of perhexiline from very sparse, routine monitoring data. Ther Drug Monit 2001; 23: 636-643.